Delivered through precision focus.


With a deep heritage and expertise across our areas of focus, we overcome challenges along every step of the R&D pathway. We’ve been around for almost one hundred years and through focused expansion of our development pipeline, we are building momentum to be around for another hundred. We are forging life-changing external partnerships, creating great possibilities and executing a strong external innovation strategy.

We are dedicating significant firepower to identify and collaborate with external innovators in the development of new assets. With the continued performance of our commercial assets as strong growth platforms, this figure will increase.

Author Image

What drives us is to make a difference. We are an organization deeply rooted in science; harnessing our expertise and collective passion we will drive innovation in Oncology, Rare Disease and Neuroscience that will deliver transformational new medicines to patients.

Christelle Huguet

EVP, Head of R&D

R&D in brief

Our R&D teams endeavor to develop innovative therapeutic solutions in our three therapeutic areas. We do this by leveraging an entrepreneurial, collaborative approach to build a sustainable portfolio and bring new treatments to patients worldwide.

Our partnerships define who we are at Ipsen

Philippe Lopes-Fernandes, Executive Vice President, Chief Business Officer on how true collaboration paves the way to innovation.

Our acceleration defines who we are at Ipsen

Christelle Huguet, Executive Vice President, Head of Research and Development on harnessing technology to accelerate the journey from discovery to innovative medicine.

Media Image

Harnessing the power of digital

We aim to be at the forefront of digital health technology to drive innovation and improve the experience of physicians and patients.

Top stories in R&D

15 March 2024 2 mins read

Applications now open for the 2024 Golden Ticket competition

As part of our commitment to accelerating transformative research and development, we’re excited to announce that our annual Golden Ticket competition is now open! Through…

22 November 2021 2 mins read

Ipsen continues to strengthen early oncology pipeline with Queen’s University Belfast collaboration and licensing agreement.

Today we are pleased to announce a partnership with the Queen’s University of Belfast (QUB), securing rights to a preclinical stage first-in-class FLIP inhibitor program,…

14 October 2022 2 mins read

Ipsen becomes a founding sponsor of the second Biolabs innovation hub in Europe at Hopital Hotel Dieu, AP-HP

Ipsen announces that it becomes a founding sponsor of the second Biolabs innovation brain hub in Europe at Hopital Hotel Dieu, AP-HP, in Paris, France….

Our R&D sites

The Group’s global R&D colleagues are located in the heart of internationally recognized scientific hubs: Paris (France), London (U.K.), Cambridge (U.S.) and Shanghai (China).

Media Image

Investigator Sponsored Studies

We are ready to consider supporting Investigator Sponsored Studies because we recognize that this research can play a key role in answering important medical and scientific questions regarding our products and/or their related therapeutic areas. Any support request must be submitted via our ISS portal.



We are supported by an active partnership policy that can go from basic research through clinical development. This is because we recognize that through external collaboration we can multiply exponentially our skills and know-how.